BONTRIL SLOW RELEASE CIII

Select the drug indication to add to your list

BONTRIL SLOW RELEASE

Obesity
Only 4 drugs may be compared at once

Generic Name and Formulations:

Phendimetrazine tartrate 105mg; slow rel caps.

Select therapeutic use:

Indications for BONTRIL SLOW RELEASE:

Short-term adjunct in managing exogenous obesity.

Adult:

105mg in the AM, 30–60 minutes before breakfast.

Children:

Not recommended.

Contraindications:

Advanced arteriosclerosis. Cardiovascular disease. Moderate or severe hypertension. Hyperthyroidism. Glaucoma. Highly nervous or agitated states. Drug or alcohol abuse. Concomitant CNS stimulants. During or within 14 days of MAOIs (see Interactions).

Warnings/Precautions:

Discontinue after a few weeks as tolerance to anorectic effect occurs. Avoid abrupt cessation after prolonged high doses. Mild hypertension. Abuse and dependence potential. Diabetes. Reevaluate after drug-free interval. Prescribe minimal supply to avoid overdose. Pregnancy.

Interactions:

Hypertensive crisis with MAOIs. May antagonize guanethidine. CNS effects with alcohol, other CNS drugs.

See Also:

BONTRIL PDM

Pharmacological Class:

Sympathomimetic.

Adverse Reactions:

Palpitation, tachycardia, hypertension, CNS overstimulation, dry mouth, GI disturbances, urinary frequency, changes in libido.

How Supplied:

Tabs—100, 1000; Caps—100